Horizon Discovery plc FCF yield
What is the FCF yield of Horizon Discovery plc?
The FCF yield of Horizon Discovery Group plc is 0.03%
What is the definition of FCF yield?
Free cash flow yield (FCF yield) is a financial ratio that compares the free cash flow per share to the market value per share. The ratio is calculated by dividing free cash flow per share by the current share price.
ttm (trailing twelve months)
Free cash flow yield is a good measure of the company’s cash flow in respect to the company’s size. Larger companies tend to have a higher cash flow yield, but it’s not always the case. The higher the free cash flow yield, the more cash the company is generating that can be quickly accessed to satisfy its obligations. The lower the free cash flow yield, the more money investors are putting into the company with little result. The higher the ratio, the more attractive the investment is as it suggests that investors are paying less for each unit of free cash flow.
Free cash flow acts as an indicator of how capable a company is of repaying all of its obligations. It is a solid indicator of how financially stable a company is. It is calculated as:
Free cash flow yield = Free cash flow per share / market price per share
FCF yield of companies in the Health Care sector on LSE compared to Horizon Discovery plc
What does Horizon Discovery plc do?
Horizon Discovery Group plc, a cell engineering company, engages in the design, manufacture, and application of gene editing and gene modulation tools in the United Kingdom, the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company operates through Screening, Research Reagents, Diagnostics, and BioProduction segments. It provides custom-made and off-the-shelf (OTS) RNAi gene modulation reagents, CRISPR reagents, synthetic SGRNAs, OTS cell models, and custom cell engineering services. The company also offers pooled CRISPR screens; arrayed RNAi and CRISPR screens, drug screens, and immunology assays; and RNAi and CRISPR screening libraries; and human T-Cell CRISPR screening service to meet the requirements of immunology based research in drug discovery. In addition, it provides OTS gene-edited CHO cells and custom CHO cell lines, and custom CHO gene engineering services; and OTS cell-based reference standards, made to order reference standards, and custom cell-based reference standards to evaluate molecular assays on a research use basis. The company serves customers in academic research labs, biopharmaceutical and diagnostics companies, and contract research and manufacturing organizations. It sells its products through direct field sales channel and e-commerce platform. The company has a partnership with the Rutgers, The State University of New Jersey to develop and commercialize base editing, a gene editing technology; strategic collaboration with Mammoth Biosciences to develop CRISPR tools to provide engineered cell lines for the biopharmaceutical industry; and collaboration with St George's University Hospital, London, and the European Molecular Genetics Quality Network to develop reference material for non-invasive prenatal testing. Horizon Discovery Group plc was founded in 2007 and is headquartered in Cambridge, the United Kingdom.
Companies with fcf yield similar to Horizon Discovery plc
- Newborn Acquisition has FCF yield of 0.02%
- Accrol plc has FCF yield of 0.02%
- DoubleDown Interactive Co has FCF yield of 0.02%
- Air Transport Services Inc has FCF yield of 0.02%
- Ryder System has FCF yield of 0.02%
- EXEL Industries SA has FCF yield of 0.03%
- Horizon Discovery plc has FCF yield of 0.03%
- Eton Pharmaceuticals has FCF yield of 0.04%
- Firsthand Technology Value Fund Inc has FCF yield of 0.04%
- Poseida Therapeutics has FCF yield of 0.04%
- Brightcove Inc has FCF yield of 0.04%
- Facephi Biometria, S.A has FCF yield of 0.05%
- Suzhou TZTEK Technology Co has FCF yield of 0.05%